However, it is currently difficult to conduct such clinical research as strong treatment centered on agents targeting the AR axis is being performed for metastatic castration-sensitive prostate cancer, so there may be no other way to speculate from the results of the DELC study. Here, AR is linked to prostate carcinoma.